Analysts favor this trio for 2026 as AI workloads push demand across chips, hyperscale cloud, and data-center connectivity.

Nektar Therapeutics just saw its fair value model refreshed, with the headline number holding steady at US$114.43 per share even as the long term revenue growth assumption for Rezpeg edged to a 10.83% ...